Agile Therapeutics, Inc. (AGRX): Price and Financial Metrics
AGRX Price/Volume Stats
Current price | $0.34 | 52-week high | $12.15 |
Prev. close | $0.37 | 52-week low | $0.20 |
Day low | $0.31 | Volume | 293,428 |
Day high | $0.41 | Avg. volume | 748,908 |
50-day MA | $1.01 | Dividend yield | N/A |
200-day MA | $1.95 | Market Cap | 1.01M |
AGRX Stock Price Chart Interactive Chart >
AGRX POWR Grades
- Sentiment is the dimension where AGRX ranks best; there it ranks ahead of 98.8% of US stocks.
- The strongest trend for AGRX is in Sentiment, which has been heading up over the past 26 weeks.
- AGRX ranks lowest in Stability; there it ranks in the 1st percentile.
AGRX Stock Summary
- AGRX has a market capitalization of $4,094,001 -- more than approximately just 2.18% of US stocks.
- With a price/earnings ratio of 0.5, AGILE THERAPEUTICS INC P/E ratio is greater than that of about only 0.21% of stocks in our set with positive earnings.
- AGILE THERAPEUTICS INC's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -196.29%, greater than the shareholder yield of just 2.26% of stocks in our set.
- Stocks that are quantitatively similar to AGRX, based on their financial statements, market capitalization, and price volatility, are OPTN, AQB, AVNS, TAYD, and AMRN.
- Visit AGRX's SEC page to see the company's official filings. To visit the company's web site, go to www.agiletherapeutics.com.
AGRX Valuation Summary
- AGRX's price/sales ratio is 0.2; this is 95.24% lower than that of the median Healthcare stock.
- AGRX's EV/EBIT ratio has moved up 6 over the prior 117 months.
Below are key valuation metrics over time for AGRX.
Stock | Date | P/S | P/B | P/E | EV/EBIT |
---|---|---|---|---|---|
AGRX | 2023-12-29 | 0.2 | -0.4 | 0.6 | 0.4 |
AGRX | 2023-12-28 | 0.2 | -0.4 | 0.6 | 0.4 |
AGRX | 2023-12-27 | 0.2 | -0.4 | 0.6 | 0.4 |
AGRX | 2023-12-26 | 0.2 | -0.4 | 0.6 | 0.4 |
AGRX | 2023-12-22 | 0.2 | -0.4 | 0.6 | 0.4 |
AGRX | 2023-12-21 | 0.3 | -0.4 | 0.6 | 0.4 |
AGRX Growth Metrics
- The 3 year cash and equivalents growth rate now stands at -67.62%.
- Its 2 year price growth rate is now at -98.54%.
- Its 5 year net income to common stockholders growth rate is now at 24.6%.
The table below shows AGRX's growth in key financial areas (numbers in millions of US dollars).
Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
---|---|---|---|
2022-09-30 | 8.403 | -51.006 | -67.011 |
2022-06-30 | 6.688 | -52.883 | -64.117 |
2022-03-31 | 5.747 | -65.285 | -69.535 |
2021-12-31 | 4.101 | -65.202 | -74.894 |
2021-09-30 | 3.337 | -65.926 | -69.157 |
2021-09-30 | 3.337 | -65.926 | -69.157 |
AGRX's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- AGRX has a Quality Grade of D, ranking ahead of 15.23% of graded US stocks.
- AGRX's asset turnover comes in at 0.06 -- ranking 307th of 682 Pharmaceutical Products stocks.
- EVFM, ARMP, and EVOK are the stocks whose asset turnover ratios are most correlated with AGRX.
The table below shows AGRX's key quality metrics over time.
Period | Asset Turnover | Gross Margin | ROIC |
---|---|---|---|
2021-09-30 | 0.060 | -0.588 | -1.478 |
2021-06-30 | 0.030 | -0.262 | -1.156 |
2021-03-31 | 0.011 | -0.668 | -0.869 |
2020-12-31 | 0.008 | 0.623 | -0.805 |
2020-09-30 | 0.000 | NA | -0.818 |
2020-06-30 | 0.000 | NA | -0.888 |
AGRX Price Target
For more insight on analysts targets of AGRX, see our AGRX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
Average Price Target | $5.00 | Average Broker Recommendation | 1.25 (Strong Buy) |
Agile Therapeutics, Inc. (AGRX) Company Bio
Agile Therapeutics, Inc. focuses on the development and commercialization of prescription contraceptive products for women. The company was founded in 1997 and is based in Princeton, New Jersey.
Latest AGRX News From Around the Web
Below are the latest news stories about AGILE THERAPEUTICS INC that investors may wish to consider to help them evaluate AGRX as an investment opportunity.
Agile Therapeutics Provides Update on Actions Being Taken to Strengthen the Affordable Care Act’s No-Cost Contraceptive Coverage RequirementThe Company Commends House Committee on Oversight and Accountability Ranking Member Jamie Raskin for New Report on Contraception Coverage Gaps New Report Follows Several Months of Activity by the Biden Administration and Lawmakers to Strengthen Access to Contraception as Defined in President Biden’s June 2023 Executive Order Implementation of the Committee’s Recommendation Could Potentially Eliminate Financial Barriers for Contraceptive Products like Twirla® for 49 Million Women PRINCETON, N.J., |
Agile Therapeutics Posts Growth In Third Quarter Results, Reiterates Confidence In Target of $25M Net Revenue, Positive Cash Flow In 2024PRINCETON, NJ / ACCESSWIRE / November 22, 2023 / Agile Therapeutics, Inc. (NASDAQ:AGRX), the commercial-stage women's healthcare company, posted a 122% increase in third-quarter revenue year-over-year, driven by strong demand for TwirlaⓇ (levonorgestrel ... |
Agile Therapeutics, Inc. (NASDAQ:AGRX) Q3 2023 Earnings Call TranscriptAgile Therapeutics, Inc. (NASDAQ:AGRX) Q3 2023 Earnings Call Transcript November 9, 2023 Agile Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.27, expectations were $-1.58. Operator: Good morning, and welcome to the Agile Therapeutics Third Quarter 2023 Financial Results Conference Call. Please note, today’s event is being recorded. I would now like to turn the […] |
Agile Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateTwirla Delivers Third Quarter 2023 Net Revenue of $6.7 Million, a 21% Increase from Second Quarter 2023 Company Announces It Expects to Generate Positive Cash Flow from Operations in First Quarter 2024 Gross Margin Grows to 63% in Third Quarter 2023 from 58% in Second Quarter 2023 Company Reaffirms Expected Full Year 2023 Net Revenue of At Least $25 Million Management to Host Conference Call Today, Thursday, November 9, 2023 at 8:30 a.m. ET PRINCETON, N.J., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Agil |
Agile Therapeutics to Report Third Quarter 2023 Financial Results and Provide Business Update on Thursday, November 9, 2023Live Conference Call and Webcast at 8:30 a.m. ET PRINCETON, N.J., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced it will report third quarter 2023 financial results before the market open on Thursday, November 9, 2023. Following the release, the Company will host a live conference call and webcast at 8:30 a.m. ET to discuss the Company’s financial results and provide a business update. EventAgile Therapeutics Third Quarter |
AGRX Price Returns
1-mo | -56.99% |
3-mo | -82.56% |
6-mo | -85.83% |
1-year | -97.07% |
3-year | -99.99% |
5-year | -99.99% |
YTD | -82.56% |
2023 | -82.82% |
2022 | -98.84% |
2021 | -82.99% |
2020 | 14.80% |
2019 | 331.03% |
Loading social stream, please wait...